Infosys AI Ki Tension, ITC Par Tax Ka Pressure, Aur LG Ka Profit Squeeze! Aaj Market Movers!

RESEARCH-REPORTS
Whalesbook Logo
AuthorKavya Nair|Published at:
Infosys AI Ki Tension, ITC Par Tax Ka Pressure, Aur LG Ka Profit Squeeze! Aaj Market Movers!
Overview

Arre bhai log, aaj market mein kuch stocks par badi khabrein hain. Infosys ko AI revenue ko lekar thoda struggle karna pad raha hai, ITC ko tax badhne se prices badhani pad rahi hain, aur LG Electronics ke profit par competition ka pressure hai. Plus, Dabur mein leadership change aur Aurobindo Pharma ke naye drug launch ki tayyariyan bhi chal rahi hain. Chalo, details mein dekhte hain kya scene hai!

Infosys: AI Ka Potential Toh Hai, Par Execution Ka Kya?

Dekho yaar, Infosys toh AI mein position toh achhi bana raha hai, aur BofA ne iska target price ₹1,840 rakha hai. Lekin asli baat yeh hai ki AI ko implement karna itna bhi seedha nahi hai. Abhi company ki AI-first offerings se revenue sirf 5.5% aa raha hai, jo baaki competitors ke barabar hi hai. Matlab, opportunity badi hai par strategy aur execution mein asli challenge hai. Share price earnings ke baad thoda gira bhi tha, kyunki investors soch rahe hain ki itna investment karne ke baad growth kitni hogi. Comparisons dekho toh TCS ka P/E 38x hai, Infosys ka 32x aur Wipro ka 28x. Matlab market Infosys se thoda kam growth expect kar raha hai. RSI toh filhaal neutral zone mein hai.

ITC: Tax Se Bachne Ke Liye Price Hike?

UBS ne ITC par 'buy' rating rakhi hai, par target price ₹420 se kam karke ₹395 kar diya hai. Distributors bol rahe hain ki cigarette prices badhne wali hain kyunki tax bahut badh gaya hai. Jo 84mm wale pack pehle ₹17 ke aate the, woh ab ₹24 ke ho jayenge. Aur 64mm wale ₹5.9 se ₹7 ho jayenge. Yahan tak ki Goldflake, jo ₹9.5 mein milta tha, woh bhi ₹12 ke aas paas ho sakta hai. Company premium segments mein price badha rahi hai taki volume par zyada impact na ho. Ye strategy peers jaise Godfrey Phillips (P/E ~22x) aur VST Industries (P/E ~20x) se thodi alag hai. Waise, ITC historicaly aise tax adjustments ke baad bhi sambhal jata hai, kyunki kuch segments mein log price elastic nahi hote.

LG Electronics: Margin Badhane Mein Mushkil?

Goldman Sachs ne LG Electronics par 'buy' rating ke saath target price ₹1,750 diya hai. Company ka growth potential achha hai, especially developing countries mein aur new product launches se. Lekin bhai, competition badh raha hai aur commodity prices bhi upar ja rahi hain. Is wajah se margin badhana mushkil ho raha hai. LG Electronics ka P/E ~12x hai, jabki Samsung Electronics ka ~18x hai, shayad Samsung ke diverse business ki wajah se. Naye OLED TVs launch hone ke baad bhi stock mein utna bounce nahi dikh raha kyunki raw material costs ka pressure hai.

Dabur: Naye CEO Ka Kya Scene?

Morgan Stanley ne Dabur par 'underweight' rating di hai aur target price ₹400 rakha hai. Company mein leadership change ho raha hai. Mohit Malhotra ab Global CEO banenge aur Herjit S Bhalla India Business ke CEO honge, yeh early 2026 se. Abhi new strategy kya hogi, yeh clear nahi hai, isliye thodi uncertainty hai. Dabur ka P/E ~52x hai, jo Marico (P/E ~50x) aur Godrej Consumer Products (P/E ~45x) se zyada hai. Aise management changes se stock mein kabhi kabhi volatility aa jati hai jab tak naye plans clear na hon.

Aurobindo Pharma: Naye Drug Ke Liye Bada Kharcha!

HSBC ne Aurobindo Pharma ko 'buy' upgrade kiya hai aur target price ₹1,415 kar diya hai. US FDA ne unke naye drug Adquey (difamilast 1%) ko approve kar diya hai, jisse $250-300 million ka brand ban sakta hai. Lekin yaar, is potential ko realize karne ke liye company ko US mein specialist sales force banane mein $50 million se $100 million per year kharch karne pad sakte hain. Aurobindo Pharma ka P/E ~17x hai, jo Dr. Reddy's (P/E ~20x) aur Sun Pharma (P/E ~22x) se kam hai. Toh potential toh hai, par launch ke liye investment aur execution risk bhi bahut bada hai.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.